Veracyte (VCYT) reported late Monday its Q4 non-GAAP earnings of $0.36 per diluted share, up from $0.21 a year earlier.
Analysts polled by FactSet expected $0.27.
Revenue for the quarter that ended Dec. 31 was $118.6 million, up from $98.2 million a year earlier.
Analysts surveyed by FactSet expected $116.7 million.
For 2025, the company said it expects testing revenue of $470 million to $480 million.
Given the number of variables impacting its Marseille, France operations, Veracyte said it is not providing total revenue outlook at this time and would provide the guidance once there is more clarity on the timing and impact of the process.
Shares of Veracyte were down over 6% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.